Dan Liu
Directeur/Membre du Conseil chez JIANGSU HUALAN NEW PHARMACEUTICAL MATERIAL CO.,LTD.
Profil
Dan Liu is an Independent Director at Jiangsu Hualan New Pharmaceutical Material Co., Ltd., a Director at Genfleet Therapeutics (Shanghai), Inc., and a Director at Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd.
He is also a Member-Supervisory Board at Innolake Pharmaceuticals (Hangzhou) Co., Ltd.
Dr. Liu previously worked as a Director at GemPharmatech Co., Ltd.
from 2019 to 2023.
He holds a doctorate degree from Yale University.
Postes actifs de Dan Liu
| Sociétés | Poste | Début |
|---|---|---|
| JIANGSU HUALAN NEW PHARMACEUTICAL MATERIAL CO.,LTD. | Directeur/Membre du Conseil | 16/10/2018 |
Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd.
 Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd. Medical SpecialtiesHealth Technology Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd. is a private company that manufactures medical equipment. The company is based in Wuxi, China. The Chinese company was founded in 1999. The CEO is Qing Song Sheng. | Directeur/Membre du Conseil | - |
Genfleet Therapeutics (Shanghai), Inc.
 Genfleet Therapeutics (Shanghai), Inc. Miscellaneous Commercial ServicesCommercial Services Genfleet Therapeutics (Shanghai), Inc. is a Chinese clinical-stage biotechnology company that focuses on developing novel drug candidates for unmet medical needs in oncology and immunology. The company is based in Shanghai, China, and was founded in 2017 by Jiong Lan and Qiang Lü. The company has built up industry-leading capabilities and expertise in developing both small molecules and biologics since its inception in 2017. Genfleet's proprietary and fully integrated R&D platform highlights multiple cutting-edge products with novel mechanisms and IP. The company's pipeline includes over 10 programs, many of which have entered multi-regional clinical trials across China. Genfleet has completed co-development partnerships with a number of publicly listed companies worldwide. Jiong Lan has been the CEO since 2017. | Directeur/Membre du Conseil | - |
Innolake Pharmaceuticals (Hangzhou) Co., Ltd.
 Innolake Pharmaceuticals (Hangzhou) Co., Ltd. Pharmaceuticals: MajorHealth Technology Innolake Pharmaceuticals (Hangzhou) Co., Ltd. is a company based in Hangzhou, China that engages in the development and commercialization of therapeutic drugs for tumors and immune system diseases. The Chinese company was founded in 2020 by Ru Lei Chen and Ming De Xia, with Ming De Xia serving as the CEO since 2020. | Directeur/Membre du Conseil | 25/03/2021 |
Anciens postes connus de Dan Liu
| Sociétés | Poste | Fin |
|---|---|---|
| GEMPHARMATECH CO., LTD. | Directeur/Membre du Conseil | 20/10/2023 |
Formation de Dan Liu
| Yale University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GEMPHARMATECH CO., LTD. | Health Technology |
| JIANGSU HUALAN NEW PHARMACEUTICAL MATERIAL CO.,LTD. | Process Industries |
| Entreprise privées | 3 |
|---|---|
Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd.
Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd. Medical SpecialtiesHealth Technology Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd. is a private company that manufactures medical equipment. The company is based in Wuxi, China. The Chinese company was founded in 1999. The CEO is Qing Song Sheng. | Health Technology |
Genfleet Therapeutics (Shanghai), Inc.
Genfleet Therapeutics (Shanghai), Inc. Miscellaneous Commercial ServicesCommercial Services Genfleet Therapeutics (Shanghai), Inc. is a Chinese clinical-stage biotechnology company that focuses on developing novel drug candidates for unmet medical needs in oncology and immunology. The company is based in Shanghai, China, and was founded in 2017 by Jiong Lan and Qiang Lü. The company has built up industry-leading capabilities and expertise in developing both small molecules and biologics since its inception in 2017. Genfleet's proprietary and fully integrated R&D platform highlights multiple cutting-edge products with novel mechanisms and IP. The company's pipeline includes over 10 programs, many of which have entered multi-regional clinical trials across China. Genfleet has completed co-development partnerships with a number of publicly listed companies worldwide. Jiong Lan has been the CEO since 2017. | Commercial Services |
Innolake Pharmaceuticals (Hangzhou) Co., Ltd.
Innolake Pharmaceuticals (Hangzhou) Co., Ltd. Pharmaceuticals: MajorHealth Technology Innolake Pharmaceuticals (Hangzhou) Co., Ltd. is a company based in Hangzhou, China that engages in the development and commercialization of therapeutic drugs for tumors and immune system diseases. The Chinese company was founded in 2020 by Ru Lei Chen and Ming De Xia, with Ming De Xia serving as the CEO since 2020. | Health Technology |